These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21930862)

  • 1. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
    Kuchenbecker RS; Reis MM; Barreiro G
    Ann Intern Med; 2011 Sep; 155(6):402; author reply 403. PubMed ID: 21930862
    [No Abstract]   [Full Text] [Related]  

  • 2. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
    Flandre P
    Ann Intern Med; 2011 Sep; 155(6):402-3; author reply 403. PubMed ID: 21930863
    [No Abstract]   [Full Text] [Related]  

  • 3. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
    Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
    Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Jan; 19(2):153-62. PubMed ID: 15668540
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.
    Manosuthi W; Sungkanuparph S; Ruxrungtham K; Prasithsirikul W; Athichathanabadi C; Tantisiriwat W; Bowonwatanuwong C; Chumpathat N; Chaovavanich A
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):127-9. PubMed ID: 18156994
    [No Abstract]   [Full Text] [Related]  

  • 7. Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.
    Elion R; Berger D; Richmond G; Sension M; Dejesus E; Cimoch P; St Clair M; Yau L; Ha B;
    HIV Clin Trials; 2010; 11(3):170-3. PubMed ID: 20736153
    [No Abstract]   [Full Text] [Related]  

  • 8. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
    Poirier JM; Guiard-Schmid JB; Meynard JL; Bonnard P; Zouai O; Lukiana T; Jaillon P; Girard PM; Pialoux G
    AIDS; 2006 Apr; 20(7):1087-9. PubMed ID: 16603872
    [No Abstract]   [Full Text] [Related]  

  • 9. PI monotherapy effective as maintenance.
    AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to "Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?" by Hill.
    Johnson M
    AIDS; 2006 Oct; 20(15):1987. PubMed ID: 16988525
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug interactions. Kaletra and atazanavir.
    TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
    [No Abstract]   [Full Text] [Related]  

  • 13. Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
    Stebbing J; Nathan B; Jones R; McKenna A; Powles T; Bower M; Holmes P; Gazzard B; Nelson M
    AIDS; 2007 Aug; 21(13):1826-8. PubMed ID: 17690587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?
    Hill A
    AIDS; 2005 Nov; 19(17):2054-5. PubMed ID: 16260922
    [No Abstract]   [Full Text] [Related]  

  • 15. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
    Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
    AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
    Mollan K; Daar ES; Sax PE; Balamane M; Collier AC; Fischl MA; Lalama CM; Bosch RJ; Tierney C; Katzenstein D;
    J Infect Dis; 2012 Dec; 206(12):1920-30. PubMed ID: 23148287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir.
    Hamzah L; Campbell L; Wandolo E; Engler B; Cheserem E; Naftalin C; Taylor C; Post FA
    AIDS; 2015 Jan; 29(3):392-4. PubMed ID: 25686688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.